Financial Performance - For the three months ended March 31, 2021, the Company reported no revenue, a decrease from $461,000 for the same period in 2020, primarily due to the transition of the Collaboration Agreement with Merck [116]. - The Company incurred a net loss of approximately $2,738,000 for the three months ended March 31, 2021, compared to a net loss of approximately $1,990,000 for the same period in 2020, representing an increase in loss of about 37% [124]. - Net cash used by operating activities was $1,770,000 for the three months ended March 31, 2021, a decrease from $2,188,000 in the same period in 2020, indicating improved cash management [125]. - The Company had $33,278,000 in cash as of March 31, 2021, and subsequently raised approximately $36.4 million from a public offering on May 7, 2021, providing sufficient capital for planned operations for over the next 12 months [129]. Research and Development - Research and development expenses increased to $1,577,000 for the three months ended March 31, 2021, compared to $1,283,000 in the same period in 2020, reflecting a rise of approximately 23% driven by COVID-19 and Influenza programs [118]. - The Company plans to initiate a Phase 1 study for its lead influenza candidate CC-42344 in the third quarter of 2021 [106]. - The Company is working towards pre-IND status with its lead coronavirus compound CDI-45205, which has shown favorable in vivo efficacy in animal studies [111]. - The Company expects to complete a proof-of-concept animal study for its norovirus program in the second quarter of 2021 [114]. - The Company has entered into an Exclusive License and Research Collaboration Agreement with Merck for the development of influenza A/B antiviral agents, with Merck now solely responsible for further development [108]. - The Company anticipates identifying an additional SARS-CoV-2 preclinical 3CL lead for oral administration within 2021 [113].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [X] Smaller reporting company [X] FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 OR [ ] T ...

NASDAQ: COCP cocrystalpharma.com C & CRYSTAL Investor Presentation March 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. ("Merck"), including the anticipated characteristics of the drug candidates developed as the result of this collaboration, expected funding by Merck of future research, developm ...

NASDAQ: COCP cocrystalpharma.com C & CRYSTAL Investor Presentation January 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. ("Merck"), including the anticipated characteristics of the drug candidates developed as the result of this collaboration, expected funding by Merck of future research, develo ...

Financial Performance - Revenue for the nine months ended September 30, 2020 was $1,504,000, a decrease of 75.6% compared to $6,162,000 for the same period in 2019[136] - Net loss for the nine months ended September 30, 2020 was $8,155,000, compared to a net loss of $324,000 for the same period in 2019[144] - Net cash used in operating activities was $7,449,000 for the nine months ended September 30, 2020, compared to $333,000 for the same period in 2019[145] - The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and has incurred operating losses since inception[150] - The Company continues to incur losses, and achieving profitability depends on the successful development, approval, and commercialization of its product candidates[158] Research and Development - Research and development expenses for the nine months ended September 30, 2020 were $5,336,000, an increase of 75.0% compared to $3,046,000 for the same period in 2019, primarily due to COVID-19 and Influenza A programs[139] - Total research and development expenses for the three months ended September 30, 2020 were $2,077,000, an increase of 92.8% compared to $1,077,000 for the same period in 2019[139] - The Company initiated a coronavirus program targeting SARS-CoV-2 and anticipates selecting its lead preclinical molecule in the fourth quarter of 2020[129] - The anticipated milestones in the Influenza program include the initiation of the Phase 1 study in 2021[159] - The Company aims to identify additional replication inhibitors in its coronavirus program and select a preclinical lead molecule in Q4 2020[159] - The Company plans to complete the proof-of-concept animal model study for its norovirus program in Q4 2020[159] Cash and Funding - The Company had $31,781,000 cash on September 30, 2020, sufficient to maintain planned operations for well beyond the next 12 months[149] - The Company received an upfront payment of $4,000,000 from Merck under the Collaboration Agreement and is eligible for milestone payments up to $156,000,000[125] - Management plans to fund future operations through additional private or public equity offerings and arrangements with strategic partners[158] Risks and Uncertainties - Risks include the impact of the COVID-19 pandemic on operations and reliance on collaboration with Merck[162] - Future liquidity is uncertain and dependent on various factors, including regulatory approvals and collaboration agreements[162] - The Company undertakes no obligation to publicly update or revise any forward-looking statements[162] Goodwill and Accounting - As of September 30, 2020, the Company had goodwill of $19,092,000, which is tested annually for impairment[164] - The Company adopted ASC Topic 606 for revenue recognition effective in Q4 2018[165]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [X] Smaller reporting company [X] Emerging growth company [ ] Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Emerging growth company [ ] Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transi ...

Collaboration and Financials - Cocrystal recognized revenue of $6560000 in 2019 from the Merck collaboration and is eligible for up to $156 million in milestone payments and royalties[8] - As of January 31, 2020, Cocrystal had 52100000 common shares outstanding[59] - As of January 31, 2020, Cocrystal's fully diluted shares outstanding were 53307139[58] - As of December 31, 2019, Cocrystal had a cash balance of approximately $7400000[59] Hepatitis C (HCV) Program - In a Phase 2a study, 67% of subjects (8 out of 12) achieved both SVR12 and SVR24, considered a virologic cure, with a 6-week treatment regimen[29] - CC-31244 demonstrated a viral load decline of 3 logs by 48 hours in HCV GT1 subjects during Phase 1b data[22] - Approximately 71 million people are infected with Hepatitis C globally[15] - Only 2% of infected Hepatitis C patients are being treated[17] Influenza Program - The global influenza market was valued at nearly $5600000000 in 2017 and is expected to reach nearly $6500000000 by 2022[34] - Influenza causes 1 billion cases annually[34] - Influenza results in up to 650000 deaths worldwide annually[35] Coronavirus (COVID-19) Program - Cocrystal expects to initiate preclinical studies of COVID-19 inhibitors in H2 2020[11] - Cocrystal acquired exclusive patent rights and know-how for coronavirus therapeutics for human use from Kansas State University Research Foundation (KSURF)[9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [X] Smaller reporting company [X] Emerging growth company [ ] FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer [ ] Accelerated filer [X] Non-accelerated filer [ ] Smaller reporting company [X] Emerging growth company [ ] Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ...